Parexel to tap additional pharmacovigilance services with QSI acquisition

By Zachary Brennan contact

- Last updated on GMT

Parexel to tap additional pharmacovigilance services with QSI acquisition

Related tags: Clinical research services, Pharmacology

Global CRO Parexel has signed a definitive agreement to acquire privately-owned, Chandigarh, India-based Quantum Solutions India, a provider of specialized pharmacovigilance services. 

The acquisition is expected to close in early April, subject to the satisfaction of closing conditions. Financial details were not revealed though Parexel said the purchase will be funded with existing cash.  The impact of the acquisition on Parexel's FY 2015 revenue and earnings per share is not expected to be material. 

Established in 2004, QSI offers a range of pharmacovigilance services including individual case safety report processing, brand physician activities, affiliate support, aggregate report writing, literature reviews, and signal detection.  The company serves pharma, medical device and consumer clients and has approximately 900 employees.

A Parexel spokeswoman did not respond to a request for comment on whether Parexel would absorb all 900 of QSI’s employees though “additional details​” will be shared when the acquisition closes.

Josef von Rickenbach, Chairman and CEO of Parexel, said, "Combined with the existing post-approval and regulatory strengths of Parexel, this acquisition will support the expansion of our pharmacovigilance services onto a broader platform.  We are excited to be able to offer our clients QSI's leading services through our Clinical Research Services business​."

The QSI business will be integrated into Parexel's Peri/Post-Approval Services group which is part of the CRS (Clinical Research Services) segment.  It is also expected to synergies with the company’s Regulatory Outsourcing Services business.

The acquisition comes as Parexel recently expanded its site network​ to speed drug delivery, as well as acquired UK-based RTSM (Randomization and Trial Supply Management) company ClinIntel​.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more